Norges Bank Takes $32.80 Million Position in Haemonetics Co. (NYSE:HAE)

Norges Bank bought a new stake in Haemonetics Co. (NYSE:HAE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 420,116 shares of the medical instruments supplier's stock, valued at approximately $32,803,000. Norges Bank owned 0.84% of Haemonetics at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Whittier Trust Co. purchased a new stake in shares of Haemonetics during the 4th quarter worth $62,000. Parkside Financial Bank & Trust boosted its position in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares in the last quarter. AlphaQuest LLC boosted its position in shares of Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares in the last quarter. KBC Group NV boosted its position in shares of Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after buying an additional 712 shares in the last quarter. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Haemonetics in the 3rd quarter worth about $204,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Needham & Company LLC decreased their price objective on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Barrington Research cut their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. JMP Securities cut their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. Finally, Raymond James reissued a "strong-buy" rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $101.22.

Remove Ads

Haemonetics Trading Down 3.1 %

Shares of NYSE HAE traded down $1.92 on Thursday, reaching $59.11. 65,546 shares of the company traded hands, compared to its average volume of 936,564. Haemonetics Co. has a fifty-two week low of $55.30 and a fifty-two week high of $97.97. The company has a 50 day moving average of $63.92 and a 200 day moving average of $73.67. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $2.97 billion, a PE ratio of 23.27, a P/E/G ratio of 1.11 and a beta of 0.41.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, equities research analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.